Sign in

CIK 0001124105

  • Accelerated filer
  • Smaller reporting company

GYRE THERAPEUTICS, INC.

Sign in to watch
Ticker
GYRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
562020050
Phone
+1 858-284-0115
Business address
12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO, CA, 92130
Former names
CATALYST BIOSCIENCES, INC., TARGACEPT INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-10-27 GNI Group Ltd. 10% owner Purchase · Series X Convertible Preferred Stock +811 $4,915.00 $4.0M 13,151
2023-10-27 GNI Group Ltd. 10% owner Purchase · Series X Convertible Preferred Stock Warrant (Right to Buy) +8,110,300 $0.13 $1.0M 8,110,300
2023-10-27 GNI Hong Kong Ltd 10% owner Other disposition −5,371,304 0
2023-10-27 GNI Hong Kong Ltd 10% owner Other disposition · Series X Convertible Preferred Stock −10,577 0
2023-08-31 Miller Seline E. SVP Finance; Interim CFO & PAO Returned to the company −6.5 0
2023-08-31 Hunt Andrea Director Returned to the company −28.23 0
2023-08-31 USMAN NASSIM President & CEO Returned to the company −24.54 0
2023-08-31 USMAN NASSIM President & CEO Returned to the company −8.46 0
2023-08-31 USMAN NASSIM President & CEO Returned to the company −1.17 0
2023-08-31 GNI Group Ltd. 10% owner Returned to the company −895.22 0
2023-08-31 GNI Group Ltd. 10% owner Returned to the company −5,371.3 0
2023-08-31 LAWLOR AUGUSTINE Director Returned to the company −24.57 0
2023-08-31 LAWLOR AUGUSTINE Director Returned to the company −24.22 0
2022-08-09 USMAN NASSIM President & CEO Purchase +3,250 $0.47 $2K 24,541
2022-08-09 Miller Seline E. SVP Finance; Interim CFO & PAO Purchase +3,250 $0.47 $2K 6,500
2022-08-09 Blouse Grant E. Chief Scientific Officer Purchase +3,250 $0.47 $2K 9,417
2022-02-11 Miller Seline E. SVP Finance; Interim CFO & PAO Grant or award · Stock Option (Right to Buy) +107,500 107,500
2022-02-11 Blouse Grant E. Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +200,000 200,000
2022-02-09 USMAN NASSIM President & CEO Purchase +3,250 $0.46 $1K 21,291
2022-02-09 Miller Seline E. SVP Finance; Interim CFO & PAO Purchase +3,250 $0.46 $1K 3,250

Page 12 of 17 · 328 trades